Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and 2025 Financial Guidance at 8 a.m. ET on January 29, 2025
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced it will release its fourth quarter and full year 2024 financial results along with 2025 financial guidance on Wednesday, January 29, 2025, at 7:00 a.m. ET. The company will host a conference call and live webcast at 8:00 a.m. ET on the same day. Participants need to register in advance to obtain call-in details. A webcast replay will be available within 24 hours after the call on Teva's investor relations website.
Teva Pharmaceutical Industries (NYSE e TASE: TEVA) ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 insieme alle previsioni finanziarie per il 2025 mercoledì 29 gennaio 2025, alle 7:00 ET. L'azienda ospiterà una conferenza telefonica e un webcast dal vivo alle 8:00 ET dello stesso giorno. I partecipanti devono registrarsi in anticipo per ottenere i dettagli per la chiamata. Una registrazione del webcast sarà disponibile entro 24 ore dopo la chiamata sul sito web delle relazioni con gli investitori di Teva.
Teva Pharmaceutical Industries (NYSE y TASE: TEVA) ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 junto con la guía financiera para 2025 el miércoles 29 de enero de 2025, a las 7:00 a.m. ET. La compañía llevará a cabo una llamada de conferencia y una transmisión en vivo a las 8:00 a.m. ET el mismo día. Los participantes deben registrarse con anticipación para obtener los detalles de la llamada. Una repetición de la transmisión estará disponible dentro de las 24 horas posteriores a la llamada en el sitio web de relaciones con inversores de Teva.
테바 제약 산업(NYSE 및 TASE: TEVA)은 2025년 1월 29일 수요일 오전 7시(ET)에 2024년 4분기 및 연간 재무 결과와 함께 2025년 재무 지침을 발표할 것이라고 발표했습니다. 회사는 같은 날 오전 8시(ET)에 회의 전화 및 실시간 웹캐스트를 진행할 예정입니다. 참가자는 전화 접속 세부정보를 얻기 위해 사전에 등록해야 합니다. 웹캐스트 재생은 통화 후 24시간 이내에 테바의 투자자 관계 웹사이트에서 이용 가능할 것입니다.
Teva Pharmaceutical Industries (NYSE et TASE : TEVA) a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 ainsi que les prévisions financières pour 2025 le mercredi 29 janvier 2025 à 7h00 ET. L'entreprise animera une conférence téléphonique et un webinaire en direct le même jour à 8h00 ET. Les participants doivent s'inscrire à l'avance pour obtenir les détails de connexion. Une rediffusion du webinaire sera disponible dans les 24 heures suivant l'appel sur le site Web des relations investisseurs de Teva.
Die Teva Pharmaceutical Industries (NYSE und TASE: TEVA) hat bekannt gegeben, dass sie am Mittwoch, den 29. Januar 2025, um 7:00 Uhr ET ihre Finanzergebnisse des vierten Quartals und des gesamten Jahres 2024 sowie die Finanzprognose für 2025 veröffentlichen wird. Das Unternehmen wird am selben Tag um 8:00 Uhr ET eine Telefonkonferenz und einen Live-Webcast abhalten. Teilnehmer müssen sich im Voraus anmelden, um die Details zur Teilnahme zu erhalten. Eine Wiederholung des Webcasts wird innerhalb von 24 Stunden nach dem Anruf auf Tevas Investor-Relations-Website verfügbar sein.
- None.
- None.
TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.
In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.
A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations.
Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and the conference call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully compete in the marketplace including our ability to successfully execute our Pivot to Growth strategy; our substantial indebtedness; our business and operations in general; compliance, regulatory and litigation matters; other financial and economic risks; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the third quarter of 2024, and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Teva Media Inquiries
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquires
TevaIR@Tevapharm.com
FAQ
When will Teva (TEVA) release its Q4 and full year 2024 earnings?
When will Teva (TEVA) announce its 2025 financial guidance?
What time is Teva's (TEVA) Q4 2024 earnings conference call?
Where can I access Teva's (TEVA) Q4 2024 earnings webcast replay?
